Abstract | BACKGROUND: METHODS: The PubMed, Embase, Cochrane, and Web of Science databases were systematically searched for relevant articles from inception until September 2022. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Subgroup analyses were performed based on disease status, TKI type, and hormone receptor status. RESULTS: CONCLUSIONS:
Trastuzumab plus TKI was better than trastuzumab monotherapy for treating different stages of HER2-positive breast cancer. The safety of trastuzumab plus TKI anti-HER2 therapy was controllable. The different efficacies of TKIs combined with trastuzumab may be related to the mechanism of action of the different TKIs, needing further investigations.
|
Authors | Lixi Li, Di Zhang, Yun Wu, Jiayu Wang, Fei Ma |
Journal | Biochimica et biophysica acta. Reviews on cancer
(Biochim Biophys Acta Rev Cancer)
Vol. 1878
Issue 6
Pg. 188969
(Aug 26 2023)
ISSN: 1879-2561 [Electronic] Netherlands |
PMID | 37640146
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2023. Published by Elsevier B.V. |